In terms of the effectiveness (benefit) of ICIs, the type of cancer, biomarkers (PD-L1 expression, microsatellite instability [MSI], and tumor mutational burden [TMB] [see commentary on recommendation]), and therapeutic effect during ICI administration are reference indicators. This evidence concerns the gene CD274 and cancer.